Comments
Indiabulls Pharmaceuticals, an Indiabulls Group company, has raised ₹155 crore from Singapore-based investment firm Clermont Group. The company will use the investments to strengthen its healthcare products and services in India, with the intention of being amongst the top 10 players in the coming decade.
“This new development provides capital for growth for years to come and puts Indiabulls Pharmaceuticals on a firm path to be a leading pharmaceutical company in the coming decade. At Indiabulls Pharmaceuticals, we want to reshape the Indian pharmaceutical industry landscape by providing next generation therapies to patients at affordable prices,” said Nikhil Chari, CEO of Indiabulls Pharmaceuticals.
“We aspire to be a patient and physician centric, innovative, best-in-class pharmaceutical company,” he added.
Indiabulls Pharmaceuticals segments span both chronic and acute therapies and across health, wellness and cosmoceutical categories with more than 300 products.
The Indiabulls Group has businesses across housing finance, consumer finance, real estate and pharmaceuticals sectors.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.